Workhorse Group Flat as Work Truck Week Dawns
Workhorse Group Inc. (NASDAQ: WKHS), an American technology company pioneering the transition to zero-emission commercial vehicles, is returning to Work Truck Week® 2025 to showcase recent additions and preview what’s next in its expanding W56 electric vehicle platform.North America’s largest work truck event, Work Truck Week, returns to the Indiana Convention Center in Indianapolis in the first week of March. More Than a Trade Show®, Work Truck Week encompasses The Work Truck Show®, Green Truck Summit, NTEA Annual Meeting, Work Truck Week Ride & Drive, educational sessions, and more.Attendees can experience the W56 208” extended wheelbase step van firsthand in the Work Truck Week Ride & Drive. This model, engineered for increased cargo capacity, recently completed durability testing simulating over 250,000 highway miles and is designed to tackle the toughest delivery and service routes. The vehicle features 1,200 cubic feet for cargo space and a custom rolling side door, providing quick, ergonomic access to the cargo area—ideal for laundry services and transporting large or bulky items.“The 10 million real-world miles our vehicles have logged tell the true story of Workhorse's electric vehicle expertise,” said Workhorse President, Commercial Vehicles Ryan Gaul, “We're proud to design and build our trucks right here in the Midwest, bringing advanced manufacturing jobs back to America's heartland.” WKHS shares lost 0.35 cents, or 0.7%, to 50 cents.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


